

FDA Mandates Breast Density Information with Mammography Results



Healthcare Law Update

FDA Mandates Breast Density Information with Mammography Results

John D. Fanburg
Chair, Healthcare

Carol Grelecki
Member, Healthcare

Harshita Rathore
Associate, Healthcare

BRACH | EICHLER^{LLC}
Counsellors at Law

4/30/2023

On March 9, 2023, the United States Food and Drug Administration (FDA) issued a [final rule](#), amending the Mammography Quality Standards Act (MQSA) of 1992, to require mammogram providers to notify women if they have dense breast tissue and recommend that they consult with a doctor about whether they need additional screening. Mammogram providers will be required to implement the new standards within 18 months.

Dense breasts have been identified as a risk factor for developing breast cancer and can make cancers more difficult to detect on a mammogram. Approximately half of the women over the age of 40 in the United States have dense breast tissue.

New Jersey implemented a similar law in 2014 which, requires mammogram providers to notify patients if they have dense breast tissue. New Jersey also requires insurers to cover breast follow-up evaluations, such as ultrasounds in women with dense breast tissue.

[Click Here to read the entire April 2023 Healthcare Law Update now!](#)

For more information, contact:

John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com

Carol Grelecki | 973.403.3140 | cgrelecki@bracheichler.com

Harshita Rathore | 973.364.8393 | hrathore@bracheichler.com